Cycle on Aug 17, 2026

I will begin by listing the open threads and watches for this topic to understand what has been tracked in past cycles and see if any specific questions require resolution or if any watches have fired.

I will now retrieve the existing notes for this topic to see what specific slugs are already in use and get a sense of the historical findings.

I see that there are several watches and threads. One very specific watch has a fire_date around today: - `019fa2b2-30f2-7453-a82b-71b8bf637885` - "Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit". The description says: "Novo Nordisk plans to file a formal motion for a preliminary injunction on August 17, 2026, to stop Eli Lilly from running comparative ads for Zepbound and Mounjaro." Wait, today's current date is August 17, 2026! Novo Nordisk plans to file the formal motion today, or maybe there's news about it. Let's search for "Novo Nordisk v. Eli Lilly", "false advertising", "preliminary injunction", "August 17 2026", "Zepbound", "Mounjaro" to see if there is any news on this lawsuit. Let's also look at other recent news in the GLP-1 space (since August 10, 2026, which is when the last notes were updated, or generally in August 2026). Key areas of interest: - Novo Nordisk v. Eli Lilly lawsuit (preliminary injunction motion or decision) - Viking Therapeutics VK2735 updates (maintenance dosing, Phase 3 prep, etc.) - Eli Lilly and Novo Nordisk earnings/supply updates or pipeline news - Health insurance coverage, Medicare price negotiations (Ozempic/Wegovy 2027 price cuts) - Medical devices (Abbott, Dexcom, bariatric surgery) - New clinical studies / applications (e.g. MASH, cardiovascular, kidney, etc.) Let's do some searches. I'll search for recent news on the Novo Nordisk vs. Eli Lilly lawsuit first.

The articles confirm that Novo Nordisk sued Eli Lilly on July 21, 2026, over false advertising. Let's search for "Novo Nordisk v. Eli Lilly" "preliminary injunction" or check if a preliminary injunction has been filed or decided. The watch says: "Novo Nordisk plans to file a formal motion for a preliminary injunction on August 17, 2026, to stop Eli Lilly from running comparative ads for Zepbound and Mounjaro." Let's see if there is any news today (August 17, 2026) regarding the filing of this motion. I will search with a query focused on the filing of this motion today.

Wait, let's search for "Novo Nordisk" "preliminary injunction" "Eli Lilly" "August 17" or "August 2026" to see if a motion was filed today, or if there is any other news. I'll search with sort: 'recent' and a query that targets the lawsuit.

Ah! The MobiHealthNews article says: "The court is scheduled to consider the motion on Aug. 17." (which is today!). And the Wall Street Journal article says: "Novo Nordisk said the motion, to be filed on Aug. 17 in New Jersey, would ask the court to stop Eli Lilly from advertising the drugs while the lawsuit proceeds." Wait, some articles (from July 24) say: "Novo Nordisk filed a preliminary injunction in New Jersey federal court Friday morning [July 24], urging a court to block ads..." and others say "The motion, to be filed on Aug. 17 in New Jersey..." or "The court is scheduled to consider the motion on Aug. 17." Let's see if there is any update on the New Jersey court docket or news today, August 17, 2026, about whether Novo Nordisk filed the motion today or if there's a hearing or decision on it today. Let's do a search on the docket or recent news.

Let's expand the search to "freshness: week" or search without freshness restrictions but sorted by date to see what was filed or scheduled on August 17, 2026.

Ah, this is extremely helpful! Let's see: 1. The Reuters article from July 28 ("Novo Nordisk must face US shareholder lawsuit over CagriSema weight loss trial") contains this crucial sentence: "A federal judge in Trenton will consider Novo Nordisk's request for a preliminary injunction to halt Eli Lilly's nationwide ads at an August 27 hearing." 2. The International Business Times Singapore article from 1 day ago ("Eli Lilly vs Novo Nordisk: What the Latest GLP-1 Drug Battle Means for Weight-Loss Patients") says: "A federal judge in New Jersey has not yet ruled on Novo's request for a preliminary injunction against Lilly's ad campaigns." 3. The PacerMonitor page says: "NOVO NORDISK INC. v. ELI LILLY AND COMPANY et al ( ... Preliminary Injunction shall be filed by no later than 08/10/2026." Wait, this means the preliminary injunction motion was actually filed (or ordered to be filed by August 10, 2026) and a hearing is scheduled for August 27, 2026, in Trenton, NJ! So the watch `019fa2b2-30f2-7453-a82b-71b8bf637885` with description "Novo Nordisk plans to file a formal motion for a preliminary injunction on August 17, 2026..." or "Preliminary Injunction Decision..." with fire_date of August 31, 2026, is still pending because the hearing is set for August 27, 2026! Wait, let's look at the watch: ID: `019fa2b2-30f2-7453-a82b-71b8bf637885` Title: "Preliminary Injunction Decision in Novo Nordisk v. Eli Lilly False Advertising Lawsuit" Fire date: August 31, 2026. Trigger: "Check for a federal court decision on Novo Nordisk's motion for a preliminary injunction in its Lanham Act lawsuit against Eli Lilly." Since the hearing is scheduled for August 27, 2026, the decision will likely come on or after August 27, 2026. This means the watch has not fired yet, but we have a concrete date for the hearing (August 27, 2026) and we can update our findings about the lawsuit. Let's look at what else is happening. Wait, let's check recent news for Viking Therapeutics (VK2735 Phase 1 maintenance dosing results or Phase 3 initiation). Let's search for "Viking Therapeutics" "VK2735" August 2026.

Let's see if we can find more details about Viking's presentation from August 2026. Wait, let's search for "Viking Therapeutics" "maintenance" "VK2735" August 2026 or "Phase 1" maintenance study results. Wait! Let's search with: `viking therapeutics vk2735 maintenance results` or `viking therapeutics "maintenance dosing"` to see if there are any updates or if it is still ongoing and expected in Q3 2026.

This is extremely useful. Let's analyze the Viking Therapeutics updates: - Viking reports cash, cash equivalents, and short-term investments of $502 million as of June 30, 2026. - Phase 3 studies evaluating subcutaneous VK2735 are called VANQUISH-1 and VANQUISH-2, which are fully enrolled and proceeding on plan. - For oral VK2735, Phase 3 trial initiation is planned for 4Q26. - What about the VK2735 maintenance dosing study? Let's check: - "The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial designed to evaluate various dosing regimens, following initial weight loss achieved with weekly VK2735 treatment." - "Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo." - "The company expects to report the results of the study in 3Q26." (This is later this quarter). - Wait, are there any other results? The pipeline page says: - "The results showed that all cohorts receiving VK2735 maintained the majority of their weight loss four weeks after receiving the final dose of VK2735 in the study (p<0.0001 vs. baseline and placebo, all cohorts). This includes the lowest dose evaluated, 2.5 mg weekly, for which 98% of the initial weight loss was maintained four weeks after the last dose was administered. In addition, follow-up assessments seven weeks after administration of the final dose demonstrated continued maintenance effects, with over 80% of the original weight loss maintained in the combined PK subset (p<0.0005 vs. baseline and placebo, all cohorts). The company believes the results support the feasibility of once-monthly dosing in the maintenance setting." Wait, are these results from the Phase 1 subcutaneous study or a previous study? Let's check the date of those results. Some of those might be from their earlier Phase 1 subcutaneous MAD study, where they looked at follow-up. Yes, "The results showed that all cohorts receiving VK2735 maintained the majority of their weight loss four weeks after receiving the final dose... This includes the lowest dose evaluated, 2.5 mg weekly..." That refers to the Phase 1 subcutaneous MAD study follow-up. The new *exploratory maintenance dosing study* (Phase 1, randomized, double-blind, placebo-controlled trial evaluating weekly, every other week, or monthly sub-q dosing, as well as oral dosing) completed enrollment (with 176 patients) and top-line data is expected in 3Q26. Let's check if there are other clinical trial updates in August 2026, or if there's any other big GLP-1 news. Let's search for "GLP-1" news in August 2026. Let's do a broad search for "GLP-1" or "obesity drug" to see what has been making headlines in the last couple of weeks.

This is amazing! I have found several outstanding and highly relevant pieces of information from August 2026: 1. **Aleniglipron Phase 2b Trial Results (Oral Small-Molecule GLP-1):** - Published in *Nature Medicine* on August 10, 2026. - Clinical trial: A randomized, double-blind, placebo-controlled Phase 2b trial of aleniglipron (an oral small-molecule GLP-1 receptor agonist being developed for obesity). - Results: After 36 weeks of treatment, average body-weight change was -9.0% (45 mg), -10.7% (90 mg), and -12.1% (120 mg) compared to -0.5% for placebo. - This represents a significant advancement in oral small-molecule GLP-1 drugs, which are highly sought after as alternatives to peptide-based injectables. 2. **Eli Lilly's Legal Action on Retatrutide Black Market (August 12, 2026):** - Eli Lilly filed six lawsuits against U.S. companies accusing them of illegally selling black-market versions of its experimental triple-agonist drug **retatrutide** (GIP/GLP-1/glucagon receptor agonist) before it has won regulatory approval. - Retatrutide is currently in Phase 3 clinical trials. Lilly is escalating its legal campaign against unauthorized sellers. - Customs and Border Protection intercepted over 690 shipments (over 31,000 units) of illicit GLP-1 drugs in FY 2025. 3. **Novo Nordisk v. Eli Lilly False Advertising Lawsuit (Preliminary Injunction Hearing Date):** - A federal judge in Trenton, New Jersey, is scheduled to consider Novo Nordisk's request for a preliminary injunction to halt Eli Lilly's nationwide comparative advertisements at a hearing on **August 27, 2026**. - Novo seeks to block Lilly's ads comparing Zepbound/Mounjaro to Wegovy/Ozempic, arguing they use outdated clinical trials (comparing highest Lilly doses to lower Novo doses) and omit Novo's newer, more potent Wegovy dose (7.2 mg, approved in March 2026) and Ozempic's 2 mg dose. - Eli Lilly defends its ads, arguing they are based on the only randomized, head-to-head clinical trial directly comparing tirzepatide and semaglutide (SURMOUNT-5). 4. **Compounded GLP-1 Regulatory Landscape (August 2026 update):** - The FDA's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List (which would close the last major regulatory pathway for large-scale compounding outsourcing facilities) had its public comment period close on **July 30, 2026**. A final determination from the FDA is pending as of August 2026. - This is a critical regulatory milestone that could severely impact the supply of compounded GLP-1s. 5. **Adolescents Obesity Treatment Shift (August 2026):** - A research letter published in *JAMA Pediatrics* (and highlighted in *JAMA* on August 14, 2026) suggests that adolescents and young adults are increasingly using GLP-1 receptor agonists to treat obesity while metabolic/surgical interventions (bariatric surgery) are declining. Let's do some more searches to drill down into: - The details of the *Nature Medicine* study on aleniglipron. Let's find out who is developing aleniglipron. Let's search "aleniglipron developer" or "aleniglipron phase 2b trial" or "aleniglipron Chugai Roche Eli Lilly" to see which pharma company owns/is developing it. - Let's search for "Eli Lilly" "retatrutide" lawsuits August 12, 2026. - Let's search for "JAMA Pediatrics" "bariatric surgery" GLP-1 August 2026 to see the details of that study. Let's do a search for "aleniglipron developer" first.

Ah! Aleniglipron is developed by **Structure Therapeutics** (formerly Gasherbrum Bio, also known as GSBR-1290)! Let's see: - "Structure's GLP-1 pill shows 'best-in-class' potential..." - "Roche commits $100M to keep its GLP-1 Structure sound" - Wait, Roche signed a patent agreement or deal with Structure Therapeutics. Let's find out what the relationship is, or if there is a patent dispute or settlement. - Let's search for "Structure Therapeutics" "aleniglipron" "Nature Medicine" August 2026 to get the exact details of the Phase 2b trial published on August 10, 2026. Let's search: `Structure Therapeutics aleniglipron "Nature Medicine" August 2026` or `"GSBR-1290" "Nature Medicine" 2026` to read more.

Ah! The search budget is spent. That is fine, we have a tremendous amount of high-quality, precise information that directly addresses the topic. Let's make sure we write up our findings. Let's review the findings we want to write/update: 1. **Novo Nordisk v. Eli Lilly False Advertising Lawsuit:** - There is an existing note with slug `novo-sues-lilly-false-advertising-glp1-2026`. Let's read this note first to see what's in there and how we should update it. - Let's check `read_notes` again or just update it. Wait, before modifying a file, let's read it first? Ah, write_note is a tool that updates the note in place. Let's fetch the note first? Wait, I don't have a specific `read_note_body` tool, but `read_notes` returns a preview. I can just write a comprehensive update that builds on the prior findings and integrates the new details (the August 27 hearing date, the specific arguments about Wegovy 7.2 mg and Ozempic 2 mg, etc.). Wait, is there a tool to read the full body? No, `read_notes` only lists title, preview, updated_at, source_count. Let's see: I can write a fresh, comprehensive note with the same slug `novo-sues-lilly-false-advertising-glp1-2026` representing the latest status as of August 17, 2026. 2. **Eli Lilly's Black-Market Retatrutide Lawsuits (August 12, 2026):** - We have an existing note with slug `retatrutide-phase3-triumph1-results-30-percent` or we can update `retatrutide-phase3-triumph1-results-30-percent` or create a new note/update `trump-lilly-stock-purchases-govt-policy-tailwinds`. - Let's check: "Eli Lilly Launches Massive Patent Litigation Campaign Against Generic Tirzepatide..." is `generic-tirzepatide-anda-sandoz-hybio-2026`. - Wait, retatrutide has a note: `retatrutide-phase3-triumph1-results-30-percent` ("Eli Lilly's Retatrutide: Clinical Efficacy, Black Market Frenzy, and Competitive Landscape"). This is the PERFECT slug to update with the new August 12, 2026, lawsuits against black-market sellers of retatrutide! Let's update `retatrutide-phase3-triumph1-results-30-percent` with the latest details on Lilly's lawsuits against 6 companies selling unauthorized retatrutide, and the CBP seizing shipments. 3. **Structure Therapeutics Aleniglipron Phase 2b Data (August 10, 2026):** - We can write a new note for this. What slug should we use? Maybe `structure-therapeutics-aleniglipron-phase2b-nature-medicine-2026`. - Wait, let's check if there are other oral GLP-1 notes. We have `kailera-hrs7535-oral-glp1-safety-efficacy` and `oral-obesity-pills-approved-medicare-glp1-bridge`. Let's create a new note specifically for aleniglipron's breakthrough Phase 2b data: `structure-therapeutics-aleniglipron-phase2b-nature-medicine-2026`. 4. **Viking Therapeutics VK2735 Updates:** - Existing note: `viking-therapeutics-vktx-ma-target-oral-vk2735-2026` ("Viking Therapeutics Advances VK2735 Pipeline: Fully Enrolls Subcutaneous Phase 3 and Targets Q4 2026 Oral Phase 3 Initiation"). - Let's update `viking-therapeutics-vktx-ma-target-oral-vk2735-2026` with the Q2 2026 financial results and pipeline update (published July 29, 2026), confirming that the subcutaneous Phase 3 VANQUISH trials are proceeding on plan, oral Phase 3 is targeted for Q4 2026, and the Phase 1 exploratory maintenance study results are still expected in 3Q26. Wait, let's look at the bariatric surgery vs. GLP-1 trend: - Existing notes: `bariatric-surgery-plunges-glp1-prescriptions-surge` and `glp1-bariatric-surgery-decline-device-impact`. - A new *JAMA Pediatrics* study was published on August 14, 2026, showing that youth obesity treatment is shifting toward GLP-1s and away from bariatric surgery. This is a perfect update for `bariatric-surgery-plunges-glp1-prescriptions-surge` or `glp1-bariatric-surgery-decline-device-impact`. Let's update `bariatric-surgery-plunges-glp1-prescriptions-surge` to include this new youth/adolescent data from August 2026. Let's do this systematically. First, let's write the note for **Novo Nordisk v. Eli Lilly False Advertising Lawsuit**. Let's review the slug: `novo-sues-lilly-false-advertising-glp1-2026`. The title is: "Novo Nordisk Seeks Preliminary Injunction in Lanham Act Lawsuit Against Eli Lilly Over 'Outdated' Comparative Ads" Let's write this note. We will cite the Reuters article from July 21, the MobiHealthNews article from July 24, and the recent Reuters/IB Times articles mentioning the August 27 hearing in Trenton, NJ. Let's make sure we include verbatim quotes and links. Let's formulate the body of `novo-sues-lilly-false-advertising-glp1-2026`: Wait, the prompt says: "Every substantive finding must: - name and link the actual thing (the story, article, paper, or page that was posted/published) — not just 'the discussion', - carry 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from (an HN comment permalink, the article URL, etc.), - then say what it means." "No YAML frontmatter — the title is the first `# ` heading and the slug is the slug parameter you pass." Let's draft the note for `novo-sues-lilly-false-advertising-glp1-2026`. Title: # Novo Nordisk Seeks Preliminary Injunction in Lanham Act Lawsuit Against Eli Lilly Over "Outdated" Comparative Ads Let's write it now.

Excellent. Now, let's write the update for **Eli Lilly's Black-Market Retatrutide Lawsuits (August 12, 2026)** under slug `retatrutide-phase3-triumph1-results-30-percent`. Let's see what the original title was: "Eli Lilly's Retatrutide: Clinical Efficacy, Black Market Frenzy, and Competitive Landscape" Let's update this note to include the new lawsuits filed on August 12, 2026, against U.S. companies selling unauthorized, black-market versions of retatrutide, which is still in Phase 3 trials. We will also include details about the massive volume of illicit GLP-1 shipments intercepted by Customs and Border Protection in FY 2025. Let's write this note.

Fantastic! Now, let's write the new note for **Structure Therapeutics' Aleniglipron Phase 2b Data (August 10, 2026)**. Let's name the slug: `structure-therapeutics-aleniglipron-phase2b-nature-medicine-2026`. Let's write this note. It will detail: - The publication in *Nature Medicine* on August 10, 2026. - The ACCESS Phase 2b clinical trial results (randomized, double-blind, placebo-controlled). - Efficacy: Up to 11.3% placebo-adjusted weight loss (12.1% absolute weight loss) at 36 weeks at the highest dose of 120 mg. - Dosing: 45 mg, 90 mg, 120 mg. - Favorable safety and tolerability profile, including data showing patients can successfully restart treatment or continue to increase dosing after an interruption. - Why this is important: Aleniglipron is an oral small-molecule GLP-1 receptor agonist. Unlike peptide-based injectables (like semaglutide/tirzepatide), small-molecule pills are highly scalable, chemically stable, and cheaper to manufacture, representing a major threat to the duopoly's injectable dominance and directly competing with Eli Lilly's near-market oral small-molecule orforglipron. Let's write this note.

Now, let's update **Viking Therapeutics' VK2735 Updates** under slug `viking-therapeutics-vktx-ma-target-oral-vk2735-2026`. Let's see what the original title was: "Viking Therapeutics Advances VK2735 Pipeline: Fully Enrolls Subcutaneous Phase 3 and Targets Q4 2026 Oral Phase 3 Initiation" Let's write an update that captures: - Viking's Q2 2026 earnings and corporate update on July 29, 2026. - Subcutaneous Phase 3 VANQUISH-1 and VANQUISH-2 trials are fully enrolled and proceeding according to plan. - Oral VK2735 is preparing for Phase 3 clinical trial initiation, expected in Q4 2026. - The exploratory Phase 1 maintenance dosing study of VK2735 (evaluating various dosing regimens—weekly, every other week, or monthly sub-q dosing, as well as daily/weekly oral dosing—following initial weight loss achieved with weekly VK2735 treatment) has completed patient enrollment with 176 patients. - Top-line results for this maintenance dosing study are expected in **3Q26** (later this quarter). This is a potential wildcard/major catalyst for the stock. Let's write this update.

Excellent. Now, let's update **Bariatric Surgery Decline and Youth GLP-1 Adoption** under slug `bariatric-surgery-plunges-glp1-prescriptions-surge`. Let's see what the original title was: "Bariatric Surgery Rates Plunge 34% as GLP-1 Prescriptions Surge 140% (JAMA Surgery Study)" Let's update this note to include: - A new study published in *JAMA Pediatrics* (highlighted in *JAMA* on August 14, 2026) showing that youth obesity treatment is shifting rapidly toward GLP-1 receptor agonists as surgical interventions (bariatric surgery) decline among adolescents and young adults. - This represents a critical expansion of the trend from the adult population into the pediatric/adolescent demographic, further squeezing the market for bariatric surgical devices and reinforcing the dominance of pharmacotherapy in obesity care. Let's write this update.

We have written all our notes. Now let's review the threads and watches to see what needs to be resolved or recorded. Wait, let's look at the threads listed in `list_threads`: - `019fa2b2-30f2-7453-a82b-71b8bf637